COMP <GO>
MED vs COST // ALTMAN Z-SCORE & DEBT/EQUITY
MEDIFAST INC (NYSE) VS. Costco Wholesale Corporation (NASDAQ) • 15-METRIC TALLY: MED 1
— COST 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: COST
LAST: $12.15 (-0.90%) • MKT CAP: $137.1M
balance-sheet
4.71
LAST: $1,012.28 (+1.78%) • MKT CAP: $441.39B
balance-sheet
9.38
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MED VS. COST)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MED | COST | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.30% | 12.82% | +58.48 | MED | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.20% | 42.43% | -52.63 | COST | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 31.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.91% | 2.09% | -1.18 | COST | /fcf-yield <GO> |
| Operating Margin | -3.70% | 3.85% | -7.55 | COST | /operating-margins <GO> |
| Net Profit Margin | -4.90% | 3.04% | -7.94 | COST | /net-margins <GO> |
| Revenue Growth (YoY) | -36.00% | 10.14% | -46.14 | COST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.14% | 0.58% | -0.44 | COST | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 4.71 | 9.38 | -4.67 | COST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | COST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 4.46% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.7 | 57.7 | -1.00 | COST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.73 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 43.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $137.1M | $441.39B | -$441.26B | COST | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MED REV | COST REV | MED GROSS % | COST GROSS % | MED FCF | COST FCF |
|---|---|---|---|---|---|---|
| FY 2026 | — | $303.15B | — | 12.8% | — | $9.38B |
| FY 2025 | $385.8M | $275.24B | 71.3% | 12.8% | $1.2M | $7.84B |
| FY 2024 | $602.5M | $254.45B | 73.8% | 12.6% | $17.0M | $6.63B |
| FY 2023 | $1.07B | $242.29B | — | 12.3% | $147.7M | $6.75B |
| FY 2022 | — | $226.95B | — | 12.2% | — | $3.50B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MED // BETA —
COST // BETA 0.73